⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653170 | 0.67 | AHR (0.47) | — | |
| SCHEMBL453581 | 0.62 | — | — | |
| SCHEMBL3807413 | 0.62 | — | — | |
| SCHEMBL23566 | 0.60 | — | — | |
| SCHEMBL130352 | 0.57 | CYP2A6 (0.33) | — | |
| SCHEMBL23314 | 0.57 | — | — | |
| SCHEMBL14487617 | 0.57 | PARP1 (0.32) | — | |
| SCHEMBL449068 | 0.55 | — | — | |
| SCHEMBL23038466 | 0.54 | — | — | |
| SCHEMBL23714123 | 0.47 | GPR84 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | claimed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | claimed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | claimed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | claimed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | claimed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1301527-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | disclosed |